Weight-loss, diabetes drugs linked to vision problems in small study [Video]

Popular drugs for diabetes and weight loss could have an unexpected side effect.

Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study at the University of British Columbia.

Some common GLP-1 drugs include Ozempic and Wegovy, which contain semaglutide as the active ingredient, and Mounjaro and Zepbound, which contain tirzepatide.

WEIGHT LOSS MAY BE HELPED BY DRINKING THIS, STUDY SUGGESTS

In the study, nine patients who were using a GLP-1 developed “ophthalmic complications,” according to the researchers. The average age of the patients was 57.4 years, according to the study findings.

Seven of the patients had nonarteritic anterior ischemic optic neuropathy (NAION), which causes vision loss in one eye.

One patient developed bilateral papillitis, which involves swollen optic nerves that can cause impaired vision, and another had paracentral acute middle maculopathy, which leads to a blind spot in the retina.

OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE …